Afaaf Liberty to Adolescent
This is a "connection" page, showing publications Afaaf Liberty has written about Adolescent.
Connection Strength
0,196
-
Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study. Lancet HIV. 2024 May; 11(5):e300-e308.
Score: 0,035
-
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial. Lancet Child Adolesc Health. 2023 10; 7(10):718-727.
Score: 0,033
-
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. N Engl J Med. 2021 12 30; 385(27):2531-2543.
Score: 0,030
-
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. Lancet Child Adolesc Health. 2021 09; 5(9):642-651.
Score: 0,029
-
Behavioral Functioning and Quality of Life in South African Children Living with HIV on Antiretroviral Therapy. J Pediatr. 2020 12; 227:308-313.e2.
Score: 0,027
-
Childhood adversity increases the risk of onward transmission from perinatal HIV-infected adolescents and youth in South Africa. Child Abuse Negl. 2018 05; 79:98-106.
Score: 0,023
-
Extent of disclosure: what perinatally HIV-infected children have been told about their own HIV status. AIDS Care. 2017 03; 29(3):378-386.
Score: 0,020